is being done in a phased manner, based on the progress of related projects. The existing equipment/facilities were also utilised to carry out research work on the Department of Biotechnology's approved projects. Therefore, the research work did not suffer on account of delay in procurement of equipment and was not carried out on inefficient equipment.

(b) and (c) The Department of Biotechnology has constituted an Expert-cum-Monitoring Committee which reviews the progress from time to time.

Action Against Marketing Executive of IDPL

461. **SHRI** MD. SALIM : Will the PRIME MINISTER be pleased to refer to the reply to Unstarred Question No. 1915 given in Rajya Sabha on the 13th May, 1993 and state :

(a) what were the alleged complaints of Director (Mktg.) of IDPL against the concerned official;

(b) the details of the letter in which the concerned official of IDPL was informed that there was no prima facie case for any action;

(c) whether it is a fact that the company was not replying to the letters of the official after receiving them and putting economic pressure on him by delaying tactics; and

(d) if so, the reasons therefor ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO) : (a) According to the information furnished by IDPL, there was no complaint from the then Director (Marketing) against the concerned official at the time of his transfer and the transfer was made on administrative grounds and was not linked to any complaint.

(b) Through letters dated 25-7-89, 14-8-89, and 21-9-89, the IDPL management informed one concerned official that his transfer was made on administrative grounds and the outcome of the preliminary enquiry from vigilance angle against him need not be communicated to him.

(c) No, Sir.

(d) Does not arise.

Charge Sheet Issued to Marketing Executive, IDPL

462. SHRIMATI SARALA MAHESHWARI : Will the PRIME MINISTER be pleased to refer to the reply to the Unstarred Question No. 1916 given in the Rajya Sabha on the 13th May, 1993 and state :

(a) the reasons of issuing charge sheet in November, 1989 to the Marketing Executive of IDPL when his leave was refused and he was declared on unauthorised absence on June 22, 1989;

(b) whether it is a fact that the rules, under which the charge sheet was issued in November, 1989, were not existing in June/July, 1989;

(c) if so, the reasons for not issuing chargesheet within a reasonable time;

(d) whether it is a fact that the management was harassing and putting economic pressure on the employee by delaying the issuing of the charge sheet when he was declared on unauthorised absence by the authorities in June, 1989, if so, the reasons therefor, and

(e) the reasons of appointing G. M. (Production) as disciplinary authority and not the G. M. (Sales) who is the line of authority as per the IDPL CDA Rules ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO) : (a) to (d) According to the IDPL, although the Marketing Executive was unauthorisedly absent from March 1989, he was given sufficient opportunities to report for duty and on the said employee's failure to comply and report for duty, a charge sheet was issued in November, 1989. There was no change in the IDPL Conduct, Discipline and Appeal Rules between June 1989 to November, 1989.

(e) As on 17-11-89, there was no General Manager (Sales) on the pay rolls of the Marketing Division. The earlier General Manager (Sales) Dr. S. S. Jolly had been transferred to the factory in Gurgaon as its General Manager.

Charges Agaisnt IDPL Official

463. SHRIMATI SARALA MAHESHWARI : Will the PRIME MINISTER be pleased to refer to the reply to the Unstarred Question No.1913 given in the Rajya Sabha on 13-5-93 and state :

(a) the charges of the Director (Mktg.) of IDPL against employee on which the inves-

tigations were made;

(b) whether any meeting took place on 14-3-1989 in the chamber of C&MD between the employees and other officials;

(c) if so, what are the details thereof; and

(d) the details of the letters dated 1-6-89, 22-6-89 and 11-7-89 respectively, issued by the Senior Personnel Manager in this regard?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) to (c) The IDPL management has reported that as per records of the company, the then Director (Marketing) of IDPL had made no charges against the said former Marketing Executive. According to IDPL, there is no record of any such meeting.

(d) The IDPL management had through three letters dated 1-6-89, 22-6-89 and 11-7-89 informed the said former Marketing Executive that no leave was being sanctioned to him and he was advised to report for duty.

BICP Report on Drug Prices

464. SHRIMATI SATYA BAHIN: Will the PRIME MINISTER be pleased to state:

(a) what are the names of bulk drugs in respect of which BICP have not sent their report on the fair prices after the announcement of DPCO, 1987;

(b) what are the prices of such bulk drugs on which the prices of major formulations are based;

(c) whether it is a fact that the producers of the bulk drugs and their formulations falling in such category are making profits at the cost of common man; and

(d) what steps have been taken to rectify the situation?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) Out of total bulk drugs under price control listed in Schedule-I & II of DPCO, 1987, BICP has submitted their recommendations in respect of 81 bulk drugs. Out of the balance, 47 bulk drugs are those which are either not manufactured in the country or are being substantially imported. The names of these 47 bulk drugs are given in the Statement-I. (*See* below). For the remaining 15 bulk drugs, the BICP has issued questionaire to the concerned manufacturers and replies are awaited. The names of these drugs are given in Statement-II.

(b) For the purpose of price fixation of formulations based on bulk drugs for which BICP has not conducted their cost-cum-technical study, the Sub-Committees of the Drugs Price Review Committee adopts weighted average landed cost of imported bulk drugs furnished by the Director General of Health Services, except in case of bulk drugs Amoxycillin, Ampicillin & Doxycycillin for which Government fixes the prices on the basis of the cost data available with it.

(c) This has not come to the notice of the Government.

(d) Does not arise.

Statement-I

SCHEDULE I

S.No.	Bulk Drug
1.	Atropine
2.	Iodoxouridine
3.	Homatropin
4.	Pyremithamine
5.	Sulphamethopyrazine

SCHEDULE II

6.	Cyproheptadine
7.	Carbamazepine
8.	Calcium Peutothenate
9.	Dipyridamole
10.	Ergometrine
11.	Griseofulvin
12.	Iron Dextran
13.	Isosorbide Dinitrate
14.	Ketoprofen
15.	Loperamide
16.	Oxythazine
17.	Pentazocine
18.	Piperazine
19.	Sulphamethizole
20.	Salazosulphapyrazine
21.	Sulphadoxine
22.	Triamterene
23.	Verapamil
24.	Neomycin